These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38052709)

  • 61. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
    Perrot A; Facon T; Plesner T; Usmani SZ; Kumar S; Bahlis NJ; Hulin C; Orlowski RZ; Nahi H; Mollee P; Ramasamy K; Roussel M; Jaccard A; Delforge M; Karlin L; Arnulf B; Chari A; He J; Ho KF; Van Rampelbergh R; Uhlar CM; Wang J; Kobos R; Gries KS; Fastenau J; Weisel K
    J Clin Oncol; 2021 Jan; 39(3):227-237. PubMed ID: 33326255
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial.
    Schjesvold F; Goldschmidt H; Maisnar V; Spicka I; Abildgaard N; Rowlings P; Cain L; Romanus D; Suryanarayan K; Rajkumar V; Odom D; Gnanasakthy A; Dimopoulos M
    Eur J Haematol; 2020 May; 104(5):443-458. PubMed ID: 31880006
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
    Necchi A; Nishiyama H; Matsubara N; Lee JL; Petrylak DP; de Wit R; Drakaki A; Liepa AM; Mao H; Bell-McGuinn K; Powles T
    BMC Urol; 2020 Nov; 20(1):181. PubMed ID: 33160359
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine.
    Danilov AV; Yimer HA; Boxer MA; Burke JM; Babu S; Li J; Mun Y; Trask PC; Masaquel AS; Sharman JP
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):121-128. PubMed ID: 34674981
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Teclistamab: First Approval.
    Kang C
    Drugs; 2022 Nov; 82(16):1613-1619. PubMed ID: 36352205
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
    Landgren O; Nadeem O
    Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
    Frerichs KA; Verkleij CPM; Mateos MV; Martin TG; Rodriguez C; Nooka A; Banerjee A; Chastain K; Perales-Puchalt A; Stephenson T; Uhlar C; Kobos R; van der Holt B; Kruyswijk S; Kuipers MT; Groen K; Vishwamitra D; Skerget S; Cortes-Selva D; Doyle M; Zaaijer HL; Zweegman S; Verona RI; van de Donk NWCJ
    Blood Adv; 2024 Jan; 8(1):194-206. PubMed ID: 38052042
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
    Cohen AD; Hari P; Htut M; Berdeja JG; Usmani SZ; Madduri D; Olyslager Y; Goldberg JD; Schecter JM; Jackson CC; Gries KS; Fastenau JM; Valluri S; Deraedt W; Akram M; Crawford R; Morrison R; Doward L; Morgan K; Seldam ST; Jakubowiak A; Jagannath S
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):68-77. PubMed ID: 36357295
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
    D'Souza A; Shah N; Rodriguez C; Voorhees PM; Weisel K; Bueno OF; Pothacamury RK; Freise KJ; Yue S; Ross JA; Polepally AR; Talati C; Lee S; Jin Z; Buelow B; Vij R; Kumar S
    J Clin Oncol; 2022 Nov; 40(31):3576-3586. PubMed ID: 36029527
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Topp MS; Zimmerman Z; Cannell P; Dombret H; Maertens J; Stein A; Franklin J; Tran Q; Cong Z; Schuh AC
    Blood; 2018 Jun; 131(26):2906-2914. PubMed ID: 29739753
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials.
    Martino M; Rossi M; Ferreri A; Loteta B; Morabito A; Moscato T; Console G; Innao V; Naso V; Provenzano PF; Recchia AG; Gentile M
    Expert Rev Hematol; 2019 Aug; 12(8):665-684. PubMed ID: 31251688
    [No Abstract]   [Full Text] [Related]  

  • 72. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
    Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
    Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
    Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
    Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
    Nielsen LK; Stege C; Lissenberg-Witte B; van der Holt B; Mellqvist UH; Salomo M; Bos G; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden A; Deenik W; Coenen J; Hinge M; Klein S; Tanis B; Szatkowski D; Brouwer R; Westerman M; Leys R; Sinnige H; Haukås E; van der Hem K; Durian M; Gimsing P; van de Donk N; Sonneveld P; Waage A; Abildgaard N; Zweegman S
    Haematologica; 2020 Jun; 105(6):1650-1659. PubMed ID: 31515355
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
    Dubois D; Dhawan R; van de Velde H; Esseltine D; Gupta S; Viala M; de la Loge C
    J Clin Oncol; 2006 Feb; 24(6):976-82. PubMed ID: 16432077
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
    Martens AWJ; Rietveld JM; de Boer R; Peters FS; Ngo A; van Mil LWHG; de Heer K; Spaargaren M; Verkleij CPM; van de Donk NWCJ; Adams HC; Eldering E; van Noesel CJM; Verona R; Kater AP
    Cancer Res Commun; 2022 May; 2(5):330-341. PubMed ID: 36875718
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
    Adenis A; Kulkarni AS; Girotto GC; de la Fouchardiere C; Senellart H; van Laarhoven HWM; Mansoor W; Al-Rajabi R; Norquist J; Amonkar M; Suryawanshi S; Bhagia P; Metges JP
    J Clin Oncol; 2022 Feb; 40(4):382-391. PubMed ID: 34730989
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma.
    Siegel D; Weisel K; Zahlten-Kumeli A; Medhekar R; Ding B; Leleu X
    Leuk Lymphoma; 2021 Dec; 62(12):3002-3010. PubMed ID: 34180331
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study.
    Ramsenthaler C; Osborne TR; Gao W; Siegert RJ; Edmonds PM; Schey SA; Higginson IJ
    BMC Cancer; 2016 Jul; 16():427. PubMed ID: 27387201
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study.
    Efficace F; Gaidano G; Petrucci MT; Niscola P; Cottone F; Codeluppi K; Antonioli E; Tafuri A; Larocca A; Potenza L; Fozza C; Pastore D; Rigolin GM; Offidani M; Romano A; Kyriakou C; Cascavilla N; Gozzetti A; Derudas D; Vignetti M; Cavo M
    Lancet Healthy Longev; 2022 Sep; 3(9):e628-e635. PubMed ID: 36102777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.